Global Fascioliasis Market – Industry Trends and Forecast to 2029

Fascioliasis Market Analysis and Size

The global fascioliasis market is expected to witness significant growth during the forecast period. According to the WHO, fascioliasis has been witnessed in more than 75 nations worldwide with the widespread infected global population of 2.4 million. The most affected areas include South America, East-Asia, and South-east Asia. Compromised hygiene and sanitation are the major reasons for the infections. The symptoms of this disease are primarily visible at 9-11 weeks of the onset of infections. The diagnosis includes eosinophil count, computer tomography scans and ultrasound. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global fascioliasis market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Fascioliasis Market Scope and Segmentation

Market Definition

Fascioliasis, also known as liver fluke infestation, is a sub-group of neglected tropical disease defined as parasitic flatworms infections caused by fasciola hepatica. The typical signs and symptoms of fascioliasis are nausea, irregular episodes of fever, abdominal pain, diarrhea and eosinophilia. Individuals infected with this infection mostly don’t show any symptoms, and sometimes symptoms arise associated with the biliary system. In rare cases, long-term complications can also develop

Global Fascioliasis Market Dynamics

Drivers

• Government Initiatives  

The government has numerous supportive schemes along with WHO to increase awareness of treatments, subsidized medicines and reimbursement policies. Government has active funding aids and programs to boost the merging drug manufacturers for fascioliasis treatment. This boosts the market growth.

• High Prevalence of Liver Fluke Infection

According to the Centers for Disease Control and Prevention (CDC), fascioliasis occurs in many areas of the world. Furthermore, fascioliasis is more prevalent in animals than in people. The number of infected people is thought to exceed two million worldwide. In addition, according to the study published in The American Journal of Tropical Medicine and Hygiene, the occurrence of 2.6 million infected and 91 million at risk of developing an infection, worldwide. This boosts the market growth.

Opportunities

• Increased Clinical Trials and Development

The increasing clinical trials and drug developmental processes are creating much opportunities for the market growth. For instance, Triclabendazole is a benzimidazole compound used regularly in veterinary practice to treat fascioliasis. In 1997, after several clinical trials using triclabendazole to treat fascioliasis, the WHO recommended the drug be placed on the essential drugs list.Thus, these factors are essential for the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs for fascioliasis being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Adverse Effects of Fascioliasis Treatment drugs

Severe adverse effects associated with the fascioliasis treatment drugs are expected to hamper the market growth. Effects related to Nitazoxanide such as nausea, discoloured urine, headache, stomach ache, then effects of Triclabendazole such as heavy sweating, dizziness, nausea, hives, itching hamper the growth of the market.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth. Although drug manufactures are thinking to reduce the cost of medicines such as Triclabendazole. Furthermore, development of more effective and safer medications such as Nitazoxanide, niclofolan emetine, chloroquine and heptachlor-para-xylol are under the process after the recommendation by WHO.

This global fascioliasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global fascioliasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Fascioliasis Market

COVID-19 pandemic has shaken the market in a big way. Several countries, such as China, the major global supplier of active pharmaceutical ingredients and chemicals, were initially infected by the virus. This has undesirably impacted the fascioliasis treatment market. Although, the global fascioliasis treatment market is anticipated to pace with the high growth trend with the restoration of normal situation. People from across the globe are increasing focus on strengthening their immunity because of the pandemic. As proteins are considered one of the significant ingredients leading to good health of an individual, the demand for high-quality milk and protein products has been increased. Thus, the awareness about various infections is also on the roll. All these factors contribute to the market size growth in the post pandemic era.

Global Fascioliasis Market Scope

The global fascioliasis market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Triclabendazole
• Nitazoxanide
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Fascioliasis Market Regional Analysis/Insights

The global fascioliasis market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global fascioliasis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global fascioliasis market throughout the forecasted period due to the high adoption of fascioliasis drugs, dependency on livestock as occupation and increased patient awareness level as well as high prevalence of leishmaniasis.

North America dominates the market due to the presence of refined healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Fascioliasis Market Share Analysis

The global fascioliasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global fascioliasis market.

Key players operating in the global fascioliasis market include:

• Emcure Pharmaceuticals Limited. (India)
• Cipla Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Johnson & Johnson Private Limited (U.S.),
• Mylan N.V. (U.S.)
• Sun Pharmaceutical Industries Limited(India)
• Aurobindo Pharma (India)
• Abbvie Inc (U.S.)
• Melinta Therapeutics, llc (U.S.)
• Janssen Global Services, LLC (U.S.)
• Norbrook (U.K.)
• Procyon Life Sciences (India)

SKU-54220